Angio-Proteomie is a private-owned biotech company, actively engaged in developing research reagents for Life Science R & D fields. We are known to offer high-quality antibodies, human primary cells, and cell lines, particularly those with GFP or RFP tagged cells for 3D models and imaging.
Meanwhile, Angio-Proteomie, is at its early stage to develop therapeutic whole human antibody using human B cell hybridoma approach.
Company Details
- Founded
- -
- Address
- 11 Park Drive,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- angioproteomie.com
- Keywords
- Antibody, Primary Cells and Cell Lines, Recombinant Proteins, Custom Based Services, IHC, Cell based Assays, Cell immortalization.
- HQ
- Boston, MA
Angio-Proteomie Questions
Angio-Proteomie's website is angioproteomie.com
Angio-Proteomie's LinkedIn profile is https://www.linkedin.com/company/angio-proteomie
Angio-Proteomie's industry is
Biotechnology Research
Angio-Proteomie's top competitors are
Diagnostic Reagents,
Kent Laboratories Inc.,
Insideoutbio,
Revolve Biotechnologies, Inc.,
Materials Science & Engineering At The University Of Delaware,
Base Peptides,
Nexus Biologics, Spc,
Labcorp,
Episode One Laboratories,
Constant Therapeutics.
Angio-Proteomie's categories are Biotechnology Research
Angio-Proteomie's founding year is 2006
